On December 18, 2023, Neurogene Inc. closed the transaction. The company has now issued 36,934,089 common shares and 23,964,846 pre-funded warrants for gross proceeds of approximately $95 million. At the closing, the securities were converted into shares of company's common Stock and $0.000001 pre-funded warrants at a rate of 0.0756 shares of common stock per share, and 0.0756 $0.000001 pre-funded warrants for each company's prefunded warrant.